WASHINGTON— This week, Congressman Fulcher backed a substantial bill in Congress to add transparency to healthcare and prescription costs in the United States. Congressman Fulcher co-sponsored Rep. Mark Meadow’s bill, H.R. 2209, the Fixing Global Free Loading Act, to establish a Chief Pharmaceutical Negotiator in the Office of the U.S. Trade Representative who will have the responsibility of negotiating with foreign governments and monitoring trade agreements, ensuring that investments made by the United States to innovate and research pharmaceuticals, benefiting the world as a whole, are reflected in the prices paid in the U.S.
Rep. Meadow’s bill is complementary to President Trump’s recent proposal, “American Patients First Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs” and actions the Administration has taken to lower the costs of healthcare and prescriptions in the United States. This includes his plan to eliminate ‘surprise billing’ and bring more transparency to health care and prescription costs, including a requirement for drug companies to include prices in television advertisements.
“I have been diligently working with my colleagues in Congress and the Administration to find improvements to the expenses of healthcare, one particular facet being prescription costs,” commented Congressman Fulcher. “I am excited by President Trump’s focus on this effort and applaud his blueprint released last week. In conjunction, Congressman Meadows has come up with an innovative plan to lower prescription costs by allowing the U.S. to negotiate on prices and leverage our cutting-edge pharmaceutical research to benefit all Americans. I’ve joined this bill as a co-sponsor and look forward to supporting additional efforts to improve our healthcare system.”
Read the full text of H.R. 2209, the Global Free Loading Act here.
Read President Trump’s full announcement here.
Read President Trump’s full report: “American Patients First Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs” here.